VEGFA and hepatocellular carcinoma: In May 2020, atezolizumab (an ICI) in combination with bevacizumab (a VEGF monoclonal antibody) was authorized as a new first-line treatment for advanced HCC based on the phase III IMbrave150 trial [14, 15].